Compare Aurora Cannabis Inc (ACB) vs Canopy Growth Corp (CGC) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

CGC trades at $0.95, down 5% on the day, with a bearish technical signal and negative earnings momentum after recent quarterly misses. The company reported a net loss of $598.12 million in 2025, with a net income margin of -222.36%, though revenue trends show some stabilization. Cash flow remains negative, and the stock faces Nasdaq listing compliance risks due to its low price, with news highlighting potential for a reverse stock split.

The outlook is highly speculative with significant operational and financial risks. While valuation ratios like P/S of 1.44 and P/B of 0.83 appear modest, persistent losses and high debt levels overshadow any near-term upside. Investor sentiment is mixed among analysts, with a slight hold bias, but the path to profitability remains uncertain amid competitive and regulatory pressures.